These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 28455075)

  • 1. Agar dilution minimum inhibitory concentrations under-represent oritavancin in vitro activity against staphylococci and enterococci.
    Arhin FF; Moeck G
    J Glob Antimicrob Resist; 2017 Jun; 9():85-86. PubMed ID: 28455075
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci.
    Yan Q; Karau MJ; Patel R
    Diagn Microbiol Infect Dis; 2018 Aug; 91(4):348-350. PubMed ID: 29678300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
    Schwalbe RS; McIntosh AC; Qaiyumi S; Johnson JA; Johnson RJ; Furness KM; Holloway WJ; Steele-Moore L
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2416-9. PubMed ID: 8891155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011.
    Morrissey I; Seifert H; Canton R; Nordmann P; Stefani S; Macgowan A; Janes R; Knight D;
    J Antimicrob Chemother; 2013 Jan; 68(1):164-7. PubMed ID: 22941898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides.
    Cercenado E; Cercenado S; Gómez JA; Bouza E
    J Antimicrob Chemother; 2003 Jul; 52(1):138-9. PubMed ID: 12805264
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents.
    Mendes RE; Castanheira M; Farrell DJ; Flamm RK; Sader HS; Jones RN
    J Glob Antimicrob Resist; 2017 Mar; 8():28-32. PubMed ID: 27939809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of human serum albumin on oritavancin in vitro activity against enterococci.
    McKay GA; Beaulieu S; Sarmiento I; Arhin FF; Parr TR; Moeck G
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2687-9. PubMed ID: 19349514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of vancomycin, linezolid, and daptomycin against staphylococci and enterococci isolated in 5 Greek hospitals during a 5-year period (2008-2012).
    Papadimitriou-Olivgeris M; Kolonitsiou F; Zerva L; Lebessi E; Koutsia C; Drougka E; Sarrou S; Giormezis N; Vourli S; Doudoulakakis A; Konsolakis C; Marangos M; Anastassiou ED; Petinaki E; Spiliopoulou I
    Diagn Microbiol Infect Dis; 2015 Dec; 83(4):386-8. PubMed ID: 26341703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections.
    Wagenlehner FM; Lehn N; Witte W; Naber KG
    Chemotherapy; 2005 May; 51(2-3):64-9. PubMed ID: 15870498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
    Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
    Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci.
    Sweeney D; Stoneburner A; Shinabarger DL; Arhin FF; Belley A; Moeck G; Pillar CM
    J Antimicrob Chemother; 2017 Feb; 72(2):622-624. PubMed ID: 27856721
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro susceptibility of Staphylococci and Enterococci to vancomycin and teicoplanin.
    Guzek A; Korzeniewski K; Nitsch-Osuch A; Rybicki Z; Prokop E
    Adv Exp Med Biol; 2013; 788():125-32. PubMed ID: 23835969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
    Belley A; McKay GA; Arhin FF; Sarmiento I; Beaulieu S; Fadhil I; Parr TR; Moeck G
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5369-71. PubMed ID: 20876372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro susceptibility to LY333328 of vancomycin-resistant enterococci isolated from humans and animals.
    van Tiel FH; van den Bogaard TE
    J Antimicrob Chemother; 1997 Nov; 40(5):733-4. PubMed ID: 9421326
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci.
    Cynamon MH; Granato PA
    Antimicrob Agents Chemother; 1982 Mar; 21(3):504-5. PubMed ID: 6213192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erroneous reporting of vancomycin susceptibility for Staphylococcus spp. by Vitek software version 2.01.
    Behera B; Mathur P
    Jpn J Infect Dis; 2009 Jul; 62(4):298-9. PubMed ID: 19628909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the BD Phoenix automated microbiology system for identification and antimicrobial susceptibility testing of staphylococci and enterococci.
    Carroll KC; Borek AP; Burger C; Glanz B; Bhally H; Henciak S; Flayhart DC
    J Clin Microbiol; 2006 Jun; 44(6):2072-7. PubMed ID: 16757600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antistaphylococcal and antienterococcal activity of the new teicoplanin amide derivative MDL 62873.
    Qadri SM; Saldin H; Ueno Y
    Chemotherapy; 1993; 39(1):55-8. PubMed ID: 8444061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
    Arhin FF; Sarmiento I; Belley A; McKay GA; Draghi DC; Grover P; Sahm DF; Parr TR; Moeck G
    Antimicrob Agents Chemother; 2008 May; 52(5):1597-603. PubMed ID: 18299406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.